Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Genetic Profiles Determine Metastasis Source

By HospiMedica staff writers
Posted on 12 Nov 2004
A study has shown that by isolating the genes that are expressed in head and neck cancer as well as those expressed in lung cancer in smokers, researchers were able to predict precisely if patients with lung masses had developed lung cancer or metastases from another source. More...
The study results were presented at the annual Clinical Congress of the American College of Surgeons (ACS) in New Orleans (LA, USA) in October 2004.

Now the researchers are making their genetic algorithms available to doctors throughout the world to help them decide whether an individual patient has advanced cancer that spread from the head and neck to the lung, or whether the patient has other metastatic sources that may be treated individually. Smokers have a high risk for developing cancer in the neck, mouth, jaw, and lung, but it is often difficult to identify the primary source of the disease because all cancers related to smoking appear the same in tissue samples under the microscope--as squamous cell carcinoma.

"People who have been smoking all their lives often have tumors in the head, in the neck, or in the tongue or jaw where the tobacco has rubbed against the inner lining of the mouth,” explained Sunil Singhal, M.D., a fellow in thoracic surgery at the University of Pennsylvania (Philadelphia, USA). "These patients also often have
masses in the chest on x-rays. There has been no way to determine whether a patient has a cancer that has spread or several different cancers.”

Dr. Singhal and his associates hope their genetic profiles of cancers related to smoking will become the new gold standard for determining if a patient has primary or metastatic disease. "We are telling physicians to look at our genes or even send tissue samples to us. We're hoping to get to the point where physicians can look on the Web, compare a patient's genetic profile with the gold standard, and be able to immediately determine what type of cancer he or she has,” said Dr. Singhal. In the study, Dr. Singhal extracted ribonucleic acid from eight smokers with lung squamous cell carcinoma and eight smokers with head and neck squamous cell carcinoma.

The researchers examined more than 44,000 genes through microarray technology to find 65 genes that could distinguish lung from head and neck cancer. After constructing statistical algorithms for each disease, the researchers prospectively classified 24 patients with an unknown primary source of head and neck or lung cancer, and they correctly identified all 17 who later were confirmed to have head and neck cancer and all seven who had lung cancer.




Related Links:
University of Pennsylvania

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Floor‑Mounted Digital X‑Ray System
MasteRad MX30+
Electric Bed
DIXION Intensive Care Bed
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.